OVV-mIL33

OVV-mIL33 is an engineered oncolytic vaccinia virus (OVV) designed to express murine interleukin-33 (mIL-33). This therapeutic candidate utilizes the dual mechanism of selective viral oncolysis and localized cytokine-mediated immune activation. The vaccinia virus vector selectively replicates within and lyses malignant cells, releasing tumor-associated antigens and initiating an inflammatory response. The expression of the mIL-33 payload acts as a potent alarmin within the tumor microenvironment, binding to its receptor, ST2 (IL1RL1), which is expressed on various immune effector cells including CD8+ T cells, natural killer (NK) cells, and type 2 innate lymphoid cells (ILC2s). This interaction promotes the recruitment and activation of these cells, thereby enhancing the systemic anti-tumor immune response and potentially overcoming resistance to immune checkpoint inhibitors. OVV-mIL33 is primarily investigated in preclinical research for the treatment of various solid tumors, including colorectal cancer and melanoma.

Other names

Oncolytic vaccinia virus expressing murine interleukin-33OVV-IL33OVV-IL-33OVV-IL 33